Avasopasem manganese is under clinical development by Galera Therapeutics and currently in Phase II for Esophagitis. According to GlobalData, Phase II drugs for Esophagitis have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Avasopasem manganese’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Avasopasem manganese overview

Avasopasem manganese is under development for the treatment of cancer and head and neck squamous cell carcinoma, locally advanced pancreatic adenocarcinoma, radiation-induced esophagitis in patients with lung cancer. It is administered by intravenous infusion route. It is a small molecule enzyme mimetic that both attacks tumors and protects normal tissues from other cancer therapies. It mimics the activity of superoxide dismutase. The drug candidate was also under development for the treatment of arthritis.

It was under development for radiation-chemotherapy-induced oral mucositis in head and neck cancer patients

It was under development for the treatment of Coronavirus Disease 2019 (COVID-19).

Galera Therapeutics overview

Galera Therapeutics (Galera) is a clinical-stage biotechnology company. It focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Its pipeline portfolio includes Avasopasem (GC4419), Rucosopasem (GC4711), clinical trials and key publications. Galera GC4419 is a small molecule enzyme mimetic that quickly converts superoxide-free radical molecules to hydrogen peroxide and oxygen which reduces the incidence, severity, and duration of severe oral mucositis. The company’s research and development unit concentrates on protection from normal tissue damage and direct anti-cancer therapy. Galera Therapeutics is headquartered in Malvern, Pennsylvania, the US.

For a complete picture of Avasopasem manganese’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.